Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data from a phase I clincal trial...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oQm553
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cutaneous squamous cell carcinoma (cSCC) are amongst the most common cancers with metastatic potential. Specific clinical and pathological “...
-
PSA! Has a TON of Scholarship Opportunities Right Now. SPOILER: college is crazy-expensive. Sorry. Did we spoil it? There are... from #Ale...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1tk1BEi via IFTTT
-
Fun math practice! Improve your skills with free problems in 'Solve two-step equations' and thousands of other practice lessons. f...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p6KhjG via IFTTT
-
Purpose. To assess the long-term clinical outcomes of conventional laser in situ keratomileusis (LASIK) for moderate to high myopia. Methods...
-
<div style=font-size:12px;text-align:center;>Vote for on globolister:<br /><a href=http:///details?site=2916&vote=1 targe...
-
How to Write a Master's Thesis. Students learning how to write a Master's Thesis will first learn that a central thesis question mus...
-
Abstract Shiga toxin-producing Escherichia coli (STEC) may cause haemolytic uraemic syndrome (HUS). Age ≤5 years and presence of stx2a a...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου